CDH1 and neoplasm: In this study, we screened over 44,000 low molecular weight (LMW) compounds from multiple compound libraries for their ability to (re)induce E-cadherin expression and to reduce tumor cell invasion in a panel of aggressive cancer types, including prostate, bladder, breast and pancreatic cancers.